Articles
7,734 Articles
Psychedelic Invest
/
Jan 17, 2025
Silo Pharma Awarded US Patent for Groundbreaking PTSD Treatment and Prepares for SPC-15 Clinical Trial
SARASOTA, FL, Jan. 08, 2025 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today...
Psychedelic Invest
/
Jan 17, 2025
Optimi Health Reports First Patients Dosed in Landmark Natural Psilocybin Study in New Zealand
Vancouver, British Columbia–(Newsfile Corp. – January 13, 2025) – Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (“Optimi” or the “Company”), a Health Canada-licensed manufacturer of psychedelic pharmaceuticals specializing in natural psilocybin and MDMA, is proud to...
Psilocybin
Psychedelic Invest
/
Jan 17, 2025
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
TORONTO, Jan. 08, 2025 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases and medical countermeasures, announced...
Psychedelic Invest
/
Jan 17, 2025
Clearmind Medicine Announces Shareholders Meeting Results
Vancouver, Canada, Jan. 07, 2025 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health...
Psychedelic Invest
/
Jan 17, 2025
Mindbio Provides Update on Multiple Phase 2B Clinical Trials and Technological Developments
Vancouver, British Columbia – TheNewswire – 15 January, 2025 – MindBio Therapeutics Corp. (CSE: MBIO); (Frankfurt: WF6), (the “Company” or “MindBio”), is a clinical stage biopharmaceutical company in psychiatric medicine development using microdoses of psychedelic medicines to...
Psychedelic Invest
/
Jan 17, 2025
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present January 12 at the Annual Neuroscience Innovation Forum
SAN FRANCISCO, CA / ACCESSWIRE / January 7, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Dr. Karen Brunke, Jaguar’s EVP of Corporate and Business Development and Acting CEO of Magdalena Biosciences, Inc. (Magdalena), the joint venture formed by Jaguar and Filament Health...
Psychedelic Invest
/
Jan 17, 2025
Cybin Launches Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry platform company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced the launch of its...
MAPS
/
Jan 15, 2025
MAPS Submits Cannabis Data Safety Update Report 2024 and Protocol Amendment to FDA on Phase 2 Study of Smoked Cannabis for Veterans with PTSD (MJP2)
On January 15, 2025, MAPS submitted to the FDA the 2024 Cannabis Data Safety Update Report (DSUR) along with a protocol amendment. The DSUR serves as the FDA Annual Report on the progress of the drug investigation over the last year. Very few updates were made to the DSUR this year, given that...
Cannabis
Psychedelics - Green Market Report
/
Jan 15, 2025
MindMed gives more detail to investors in latest presentation
Psychedelic drug company Mind Medicine Inc. (MindMed) (NASDAQ: MNMD) published its 2025 Investor Presentation this week with more detail on its plans than the company’s 2024 presentation. The company was sitting on a generous cash cushion last year but has now added an additional $250 million...
Psychedelics Today
/
Jan 14, 2025
Kama Flight: The Healing Power of Somatic Movement, Communication, and Trust
As society becomes more virtual and disconnected, many of us are looking for new ways to touch, feel, and connect. What is Kama Flight, and how can it be used with psychedelics? In this episode, Joe interviews Jeremy Falk: certified instructor and training program developer for Kama Flight; and Dr....
DoubleBlind Mag
/
Jan 13, 2025
How to Help People Affected by the Los Angeles Fires
SERVICES FOR THOSE AFFECTED Find shelter, chargers, food, pet boarding, and other services here Here are brands providing products to people affected VOLUNTEER Check this spreadsheet for up-to-date volunteer opportunities. Note that you can just show up to some places, while other places require...
Psychedelic Invest
/
Jan 13, 2025
atai Life Sciences Announces Key Leadership Appointments as it Advances its Pipeline of Novel Psychedelic Therapeutics for Mental Health
NEW YORK and BERLIN, Jan. 10, 2025 (GLOBE NEWSWIRE) — atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced key leadership appointments to advance its goal of...
DMT
Microdose
/
Jan 13, 2025
The Innovators Shaping the Future of Psychedelic Science
The field of psychedelic science and therapy is advancing at an unprecedented pace, driven by a diverse group of researchers, clinicians, and thought leaders committed to unlocking the therapeutic potential of these powerful substances. From groundbreaking studies on addiction and mental health to...
DMT
MDMA
Psilocybin Alpha
/
Jan 10, 2025
Pα+ Psychedelic Bulletin #185: Joe Rogan on Ibogaine; Wisconsin Medicaid to Cover IV Ketamine for Depression; Inside the Plan to Make Lykos MAPS Again
Last Friday, former Texas Governor Rick Perry and ibogaine evangelist Bryan Hubbard appeared on The Joe Rogan Experience podcast for a two-hour interview with the titular personality. The episode began with the retired Republican politician, Perry, recounting the story of how he befriended Marcus...
Ketamine
Psychedelics Today
/
Jan 07, 2025
Can Legalization Serve the Greater Good? The Ethical Challenges of Psychedelic Law
In this episode, Joe interviews Ariel Clark: Anishinaabe attorney and co-founder of the Psychedelic Bar Association, a national association of lawyers involved in the highly-regulated ecosystem of psychedelic law. She talks about ethics: How do the different societal norms of each lineage we carry...
Psychedelic Invest
/
Jan 06, 2025
SciSparc-Clearmind Medicine Collaboration Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment
TEL AVIV, Israel, Jan. 06, 2025 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced today as part of its ongoing...
Psychedelic Invest
/
Jan 06, 2025
Algernon Pharmaceuticals Receives Notice of Allowance from USPTO For Repirinast in Kidney Disease Patent
VANCOUVER, British Columbia, Jan. 06, 2025 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a clinical stage pharmaceutical development company, is pleased to announce that it has received a notice of allowance...
DMT
Psychedelic Invest
/
Jan 06, 2025
Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 8th Annual Neuroscience Innovation Forum During “J.P. Morgan Week 2025”
Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced Joseph Tucker, Ph.D., CEO, will...
Psychedelic Invest
/
Jan 06, 2025
Optimi Health Completes Second MDMA Shipment to Australia and Expands 2025 Production Forecast to Support Over 5,000 Patients Globally
Vancouver, British Columbia–(Newsfile Corp. – January 6, 2025) – Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (“Optimi” or the “Company“), a Health Canada-licensed manufacturer of psychedelic pharmaceuticals specializing in natural psilocybin and MDMA, is pleased to...
MDMA
Psychedelic Invest
/
Jan 06, 2025
The Psychedelic Industry in 2025: Key Trends and Opportunities
As 2025 begins, the psychedelic industry stands at a critical turning point, with advances in clinical research, regulatory shifts, and growing cultural acceptance reshaping its trajectory. Experts predict that psychedelics will play an increasingly vital role in addressing mental health challenges,...
Psychedelic Invest
/
Jan 06, 2025
The Psychedelics Industry Hit Major Highs and Lows in 2024
The psychedelics industry witnessed notable milestones and setbacks at both the state and federal levels in 2024. Here’s a detailed look at some of the most significant events of the year. Department of Veterans Affairs Funds Psychedelic Research for Veterans In a landmark move, the Department of...
MDMA
Psychedelics
Microdose
/
Jan 06, 2025
Healing Sexual Assault Trauma with Psychedelic Journeys: Potentials and Pitfalls
The path to healing from sexual assault trauma is often complex, deeply personal, and fraught with challenges. In recent years, however, a quiet revolution in mental healthcare has begun to reshape how we approach trauma recovery. Traditional trauma-focused exposure therapy—long considered the...
Ketamine
Psychedelics
Psychedelics Today
/
Jan 03, 2025
Pot for the People: Debunking Cannabis Myths and Empowering Consumers
What is RSO? What is THC-A? Do sativa and indica really mean what we think? How much do we really know about cannabis? In this episode, Joe interviews Angie Roullier: longtime veteran of the cannabis industry and author of the book, Pot for the People: The Plant, the People, and the Shop Policies of...
Cannabis
Psychedelic Invest
/
Jan 03, 2025
Hope Therapeutics, Inc. and NRx Pharmaceuticals, Inc. Announce Kadima Neuropsychiatry Institute as the Expected First Acquisition for its International Network of Interventional Psychiatry Clinics
MIAMI – HOPE Therapeutics, Inc., (‘HOPE,’ the ‘Company’), a medical and technology driven company, and a wholly-owned subsidiary of NRx Pharmaceuticals, Inc. (‘NRx’) (Nasdaq: NRXP), today announced the planned acquisition of the Kadima Neuropsychiatry Institute (Kadima) of La...
Ketamine
Psychedelic Invest
/
Jan 02, 2025
Silo Pharma Issues Letter to Shareholders Detailing Development Progress and Potential for Lead Assets Targeting PTSD and Chronic Pain
SARASOTA, FL, Jan. 02, 2025 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” “we,” “us,” “our,” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and...
Psychedelic Invest
/
Jan 02, 2025
Numinus Provides Bi-Weekly Update on Annual Filings
VANCOUVER, BC, Jan. 1, 2025 /PRNewswire/ – Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) (“Numinus” or the “Company“), a leader in mental health care specializing in innovative and evidence-based treatments, today provided an update with respect to its previously announced...
Psychedelic Invest
/
Jan 02, 2025
Clearmind Medicine Granted Patent for Binge Behavior Treatment by the Macau International Intellectual Property Office
Vancouver, Canada, Jan. 02, 2025 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health...
Psychedelics Today
/
Jan 02, 2025
Vital Training: Live Informational Session and Q+A
Vital FAQ WebinarJoin us for a free webinar where we’ll dive into everything you need to know about the Vital, our 12-month psychedelic education program for medical specialists, mental health professionals, therapists, and wellness practitioners. In this interactive session, we’ll cover:...
Psychedelics Today
/
Dec 31, 2024
How Psychedelics Can Help Build a Better You: The Power in Letting Go
In this episode, Kyle interviews Tommy Aceto: former Navy Seal and trauma medic, and now, ambassador for the Veteran Mental Health Leadership Coalition and advisor at Beond Ibogaine. He talks about how much the psychedelic space focuses on healing and mental health, but doesn’t talk enough about...
Psychedelics
Psilocybin Alpha
/
Dec 30, 2024
Pα+ Psychedelic Bulletin #184: Federal Psychedelics Lobbying Jumps 90% in Q3’24, with MDMA-AT the Key Topic
Earlier this year, we published an overview of federal lobbying efforts related to psychedelics, based on filings by organisations like advocacy groups, other nonprofits and drug developers. Of course, these figures don’t entirely capture efforts to lobby members of the federal government—and...
Psychedelics
Psychedelics Today
/
Dec 27, 2024
Taking the Leap: Skydiving, Psychedelics, and Unlocking Personal Potential
In this episode, Joe interviews Melanie Curtis: world record professional skydiver, keynote speaker, coach, co-host of the Trust the Journey podcast, and author of How to Fly: Life Lessons From a Professional Skydiver. Curtis shares her journey from taking her first transformative leap out of an...
Psychedelic Invest
/
Dec 26, 2024
Clearmind Medicine Looks to Move Forward with its Novel Psychedelic MEAI- Based Alcohol Substitute
Vancouver, Canada, Dec. 26, 2024 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health...
Psychedelic Invest
/
Dec 26, 2024
Clearmind Medicine Receives IRB Approval for its FDA-Regulated Clinical Trial
Vancouver, Canada, Dec. 24, 2024 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health...
DoubleBlind Mag
/
Dec 26, 2024
Monotubs 101: A Beginner’s Guide to One of the Cornerstones of Indoor Mushroom Cultivation
The interest in all things fungi, and in particular, a curiosity about their medicinal benefits, has been rapidly growing in the past few years. This curiosity has led more people to take an interest in mushroom cultivation, an odd but equally consuming hobby quite unlike gardening, and in many ways...
DoubleBlind Mag
/
Dec 25, 2024
The Origins of Lizard King Strain
The identity of Lizard King remains unknown, although over years of activity at Shroomery LK has shared pictures of hunting expeditions, opening a dredging business, having a room in his house dedicated to bearded dragons, car accidents, and legal troubles. “I am the Lizard King, I can do...
Psychedelics Today
/
Dec 24, 2024
Rethinking Addiction and Treatment Models: Is the Recovery Community Ready for Psychedelics?
Psychedelics are going mainstream, but society’s views on addiction and recovery models are still behind. Is the recovery community ready for psychedelics? In this episode, Joe interviews Dan Ronken: licensed professional counselor and addiction counselor with a private practice in Boulder, CO,...
Psychedelics
